Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Shih-Shih Chen, PhD, Constantine S. Tam, MBBS (Hons), MD, Alan G. Ramsay, BSc,MSc,PhD, Priyadarshini Ravichandran, Natalia C. Couto-Francisco, Michael Ibrahim, Gerardo Ferrer, PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, He Zhou, Jacqueline C Barrientos, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2019) 134 (Supplement_1): 477.

https://doi.org/10.1182/blood-2019-127255

Published: 2019

Journal Articles

Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells

Alicia Vaca, PhD, Mariela Sivina, Karen Clise-Dwyer, PhD, Ekaterina Kim, MS, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Dan Li, PhD, Qing Ma, PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 1746.

https://doi.org/10.1182/blood-2019-125827

Published: 2019

Journal Articles

Platelet Desialylation As a Predictive Marker in Childhood Immune Thrombocytopenia (ITP)

Leona Raskova Kafkova, MSc, PhD, Diana Brokesova, MSc, Zbynek Novak, MD, Milan Raska, Prof. MD MSc, PhD, Dagmar Pospisilova, Prof MD PhD, Jana Volejnikova, MD

Blood (2019) 134 (Supplement_1): 221.

https://doi.org/10.1182/blood-2019-122095

Published: 2019

Journal Articles

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 4342.

https://doi.org/10.1182/blood-2019-129680

Published: 2019

Journal Articles

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lacey S. Williams, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 5697.

https://doi.org/10.1182/blood-2019-122932

Published: 2019

Journal Articles

Active Immune Thrombocytopenia (ITP) Disease Is Characterised By a Reduced Treg:CD8 Effector T Cell Ratio Which Is Modulated By Thrombopoietin-Receptor Agonists (TPO-RA)

Anwar A. Sayed, MBBS, MSc, Amna Malik, PhD, Ahmad Khoder, MD PhD MRCP, George Adams, MBChB, Nichola Cooper, MRCP

Blood (2018) 132 (Supplement 1): 2430.

https://doi.org/10.1182/blood-2018-99-113563

Published: 2018

Journal Articles

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

Kidist Ashami, BA, Kiran R. Vij, MD, Julie Ritchey, Srikanth Santhanam, PhD, Karl W. Staser, MD PhD, Sora Lim, Sena Kim, Matthew L. Cooper, PhD, Feng Gao, PhD, Matthew Ciorba, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2018) 132 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2018-99-119470

Published: 2018

Journal Articles

Deregulated Expression of Long Non-Coding RNA AC092580.4 in Acute Myeloid Leukemia

Yachun Jia, Yuandong Feng, MD, Ying Shen, MD, Hongli Chen, Ru Zhang, MD, Yue Peng, Yun Yang, MD, Ju Bai, PhD, Jian-Li Wang, MD PhD, Baiyan Wang, MD PhD, Fang-Xia Wang, MD PhD, Aili He, MD

Blood (2018) 132 (Supplement 1): 5254.

https://doi.org/10.1182/blood-2018-99-114917

Published: 2018

Journal Articles

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Marzia Palma, MD PhD, Kia Heimersson, Tom A. Mulder, MD, Barbro Näsman-Glaser, Anders Österborg, MD PhD Prof., Håkan Mellstedt, MD PhD

Blood (2018) 132 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2018-99-110236

Published: 2018

Journal Articles

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Jingying Dai, PhD, Xi Yang, Xiaobing Huang, Hong Zheng, MD PhD, Xiaodong Wang, MD

Blood (2018) 132 (Supplement 1): 4272.

https://doi.org/10.1182/blood-2018-99-113032

Published: 2018

Journal Articles

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2018-99-113282

Published: 2018

Journal Articles

Peritoneal Cavity Cells Ameliorate Graft-Versus-Host Disease of Mice after MHC Mismatched Bone Marrow Transplantation

Zhigang Liu, MD, Wanhua Zhang, MD, Xinchuan Chen, MD, Chuan He, MD, Jie Ji, MD, Ting Liu, MD

Blood (2018) 132 (Supplement 1): 5675.

https://doi.org/10.1182/blood-2018-99-114510

Published: 2018

Journal Articles

Evidence That Some Breast Implant Associated Anaplastic Large Cell Lymphomas Arise in the Context of Allergic Inflammation

Marshall E. Kadin, MD, Alan L. Epstein, MD, William Adams, Jr., MD, Caroline Glicksman, MD, David Sieber, MD, Bradley A Hubbard, MD, L. Jeffrey Medeiros, MD, Mark W Clemens, MD, Roberto N. Miranda, MD

Blood (2017) 130 (Supplement 1): 4030.

https://doi.org/10.1182/blood.V130.Suppl_1.4030.4030

Published: 2017

Journal Articles

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Eric D. Hsi, MD, Hongli Li, MS, Andrew B. Nixon, PhD, Andrew M Evens, DO,MSc, Heiko Schoder, MD, David J. Straus, MD, Nancy L. Bartlett, MD, John William Sweetenham, MDFRCP, Paul M. Barr, MD, Michelle A. Fanale, MD, James R. Cook, MD PhD, Brad S Kahl, MD, John P. Leonard, MD, Sonali M. Smith, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 4033.

https://doi.org/10.1182/blood.V130.Suppl_1.4033.4033

Published: 2017

Journal Articles

Perturbation in B Cell-Subsets Can Explain the Observed Suppression of Uninvolved Immunoglobulins and Their Impact on T Tell-Subsets As Well As Patients Outcome in Myeloma

Rao Prabhala, PhD, Shree Acharya, MS, Megan Stekla, BS, Srikanth Talluri, PhD, Raphael Szalat, MD, Puru Nanjappa, Michael A Lopez, BS, Kenneth Wen, BS, Chaitanya Yenumula, MD, Alexander Heubeck, BS, Yu-Tzu Tai, PhD, Ansh Mehta, MBBS, Mariateresa Fulciniti, PhD, Suzan Lazo-Kallanian, BS, John Daley, PhD, Paul G Richardson, MD, Kenneth C Anderson, MD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 3049.

https://doi.org/10.1182/blood.V130.Suppl_1.3049.3049

Published: 2017

Journal Articles

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Blood (2016) 128 (22): 1346.

https://doi.org/10.1182/blood.V128.22.1346.1346

Published: 2016

Journal Articles

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Bing Wang, Julie Ritchey, Bader Alahmari, MD, Matthew Holt, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3353.

https://doi.org/10.1182/blood.V128.22.3353.3353

Published: 2016

Journal Articles

Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response

Tomoki Ito, M. D. and Ph. D., Phan Thi Xuan Vien, Muneo Inaba, Ph. D, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MD MPH, PhD, Shosaku Nomura, MD PhD

Blood (2016) 128 (22): 2520.

https://doi.org/10.1182/blood.V128.22.2520.2520

Published: 2016

Journal Articles

Treatment and Prognosis in Patients with Adult T-Cell Leukemia-Lymphoma (ATL): A Nationwide Survey in Japan

Yoshitaka Imaizumi, MD, PhD, Masako Iwanaga, MD, PhD, Kisato Nosaka, MD, PhD, Shigeki Ito, MD, PhD, Kenji Ishitsuka, MD, PhD, Atae Utsunomiya, MD, PhD, Yoshiki Tokura, MD, PhD, Takeaki Tomoyose, MD, PhD, Kazuya Shimoda, MD, PhD, Kensei Tobinai, MD, PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD, PhD, Kunihiro Tsukasaki, MD

Blood (2016) 128 (22): 5936.

https://doi.org/10.1182/blood.V128.22.5936.5936

Published: 2016

Journal Articles

Profound Hypereosinophilia Secondary to Sezary Syndrome

Ardy Davarifar, MD, Ricklie Julian, MD, Pareek Vipul, MD, Emrullah Yilmaz, MD, Amit Verma, MD

Blood (2015) 126 (23): 5053.

https://doi.org/10.1182/blood.V126.23.5053.5053

Published: 2015

NARROW

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells

Platelet Desialylation As a Predictive Marker in Childhood Immune Thrombocytopenia (ITP)

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Active Immune Thrombocytopenia (ITP) Disease Is Characterised By a Reduced Treg:CD8 Effector T Cell Ratio Which Is Modulated By Thrombopoietin-Receptor Agonists (TPO-RA)

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

Deregulated Expression of Long Non-Coding RNA AC092580.4 in Acute Myeloid Leukemia

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Peritoneal Cavity Cells Ameliorate Graft-Versus-Host Disease of Mice after MHC Mismatched Bone Marrow Transplantation

Evidence That Some Breast Implant Associated Anaplastic Large Cell Lymphomas Arise in the Context of Allergic Inflammation

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Perturbation in B Cell-Subsets Can Explain the Observed Suppression of Uninvolved Immunoglobulins and Their Impact on T Tell-Subsets As Well As Patients Outcome in Myeloma

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response

Treatment and Prognosis in Patients with Adult T-Cell Leukemia-Lymphoma (ATL): A Nationwide Survey in Japan

Profound Hypereosinophilia Secondary to Sezary Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only